Although fatigue is one of the most problematic symptoms for people with systemic sclerosis, little is known about how fatigue impacts daily life over time. Such information is important when developing fatigue management interventions. This study was conducted to examine (1) if fatigue severity predicted outcomes of worse functioning (social participation, physical function), and quality of life and (2) if level of self-efficacy moderated significant relationships between fatigue and these outcomes.
Methods:
Data were utilized from a clinical trial in which an online self-management intervention was tested (N = 267). Fatigue, social participation, and physical function were assessed by PROMIS measures. Quality of life was assessed by the EuroQol 5-domain instrument. Linear regressions were performed to examine how baseline fatigue related to functioning and quality of life outcomes 16 weeks later controlling for relevant covariates. PROMIS measures were used to measure self-efficacy in managing symptoms, daily activities, medications and treatments, emotions, and social interactions.
Results:
Fatigue at baseline significantly predicted social participation 16 weeks later, but did not predict physical functioning or quality of life. Self-efficacy variables did not moderate the association between fatigue and social participation.
Conclusion:
Fatigue severity predicted decreased social participation in people with systemic sclerosis. Interventions targeting fatigue should include support to maintain participation of social roles and activities. The level of reported self-efficacy did not vary the strength of the association between fatigue and decline in social participation indicating that there may be other targets to treat fatigue intervention beyond self-management.
MayesMDLaceyJVJrBeebe-DimmerJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum2003; 48(8): 2246–2255.
3.
BasselMHudsonMTailleferSS, et al. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford)2011; 50(4): 762–767.
4.
BastaFAfeltraAMargiottaD.Fatigue in systemic sclerosis: a systematic review. Clin Exp Rheumatol2018; 36: 150–160.
5.
RichardsHLHerrickALGriffinK, et al. Systemic sclerosis: patients’ perceptions of their condition. Arthritis Care Res2003; 49(5): 689–696.
6.
SanduskySBMcGuireLSmithMT, et al. Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology (Oxford)2009; 48(2): 165–169.
7.
van LankveldWGVonkMCTeunissenH, et al. Appearance self-esteem in systemic sclerosis—Subjective experience of skin deformity and its relationship with physician-assessed skin involvement, disease status and psychological variables. Rheumatology (Oxford)2007; 46(5): 872–876.
8.
NakayamaATunnicliffeDJThakkarV, et al. Patients’ perspectives and experiences living with systemic sclerosis: a systematic review and thematic synthesis of qualitative studies. J Rheumatol2016; 43(7): 1363–1375.
9.
SandqvistGSchejaAHesselstrandR.Pain, fatigue and hand function closely correlated to work ability and employment status in systemic sclerosis. Rheumatology (Oxford)2010; 49(9): 1739–1746.
10.
SharifRMayesMDNicassioPM, et al. Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohort. Semin Arthritis Rheum2011; 41(1): 38–47.
11.
SinghMKClementsPJFurstDE, et al. Work productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study. Arthritis Care Res (Hoboken)2012; 64(2): 176–183.
12.
PooleJLHaygoodDMendelsonC.“I’m still dad”: the impact of scleroderma on being a father. Occup Ther Health Care2018; 32(1): 1–13.
13.
PooleJLWillerKMendelsonC.Occupation of motherhood: challenges for mothers with scleroderma. Am J Occup Ther2009; 63(2): 214–219.
14.
PooleJLWillerKMendelsonC, et al. Perceived parenting ability and systemic sclerosis. Musculoskeletal Care2011; 9(1): 32–40.
15.
AssassiSLeyvaALMayesMD, et al. Predictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. PLoS One2011; 6(10): e26061.
16.
WillemsLMKwakkenbosLVonkMC, et al. Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study. Clin Exp Rheumatol2017; 35 Suppl106(4): 48–55.
17.
MurphySKratzAWhibleyD, et al. Fatigue and its association with social participation, functioning and quality of life in systemic sclerosis. Arthritis Care Res. Epub ahead of print 16 December 2019. DOI: 10.1002/acr.24122.
18.
PeytrignetSDentonCPLuntM, et al. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European scleroderma observational study. Rheumatology2018; 57(2): 370–381.
19.
DayMAEhdeDMJensenMP.Psychosocial pain management moderation: the limit, activate, and enhance model. J Pain2015; 16(10): 947–960.
20.
EhdeDMArewasikpornAAlschulerKN, et al. Moderators of treatment outcomes after telehealth self-management and education in adults with multiple sclerosis: a secondary analysis of a randomized controlled trial. Arch Phys Med Rehabil2018; 99(7): 1265–1272.
21.
MarksRAllegranteJPLorigK.A review and synthesis of research evidence for self-efficacy-enhancing interventions for reducing chronic disability: implications for health education practice (part I). Health Promot Prac2005; 6(1): 37–43.
22.
KhannaDSerranoJBerrocalVJ, et al. Randomized controlled trial to evaluate an internet-based self-management program in systemic sclerosis. Arthritis Care Res (Hoboken)2019; 71(3): 435–447.
23.
RoseAJBaylissEHuangW, et al. Evaluating the PROMIS-29 v2.0 for use among older adults with multiple chronic conditions. Qual Life Res2018; 27(11): 2935–2944.
24.
HinchcliffMBeaumontJLThavarajahK, et al. Validity of two new patient-reported outcome measures in systemic sclerosis: patient-reported outcomes measurement information system 29-item health profile and functional assessment of chronic illness therapy-dyspnea short form. Arthritis Care Res (Hoboken)2011; 63(11): 1620–1628.
25.
HerdmanMGudexCLloydA, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res2011; 20(10): 1727–1736.
26.
PickardASLawEHJiangR, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health2019; 22(8): 931–941.
27.
Gruber-BaldiniALVelozoCRomeroS, et al. Validation of the PROMIS((R)) measures of self-efficacy for managing chronic conditions. Qual Life Res2017; 26(7): 1915–1924.
28.
HinzAKohlmannTStobel-RichterY, et al. The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population. Qual Life Res2014; 23(2): 443–447.
29.
McCaffreyNKaambwaBCurrowDC, et al. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms. Health Qual Life Outcomes2016; 14(1): 133.
30.
MullerHRehbergerPGuntherC, et al. Determinants of disability, quality of life and depression in dermatological patients with systemic scleroderma. Br J Dermatol2012; 166(2): 343–353.
31.
StricklandGPaulingJCavillC, et al. Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools. Clin Rheumatol2012; 31(8): 1215–1222.
GignacMAMCottCBadleyEM. Adaptation to chronic illness and disability and its relationship to perceptions of independence and dependence. J Gerontol B Psychol Sci Soc Sci2000; 55(6): P362–P372.
34.
KatzPMorrisATrupinL, et al. Disability in valued life activities among individuals with systemic lupus erythematosus. Arthritis Care Res2008; 59(4): 465–473.
35.
KatzPPMorrisAYelinEH.Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis. Ann Rheum Dis2006; 65(6): 763–769.
36.
PooleJLChandrasekaranAHildebrandK, et al. Participation in life situations by persons with systemic sclerosis. Disabil Rehabil2015; 37(10): 842–845.
37.
SierakowskaMDoroszkiewiczHSierakowskaJ, et al. Factors associated with quality of life in systemic sclerosis: a cross-sectional study. Qual Life Res2019; 28(12): 3347–3354.
38.
ThombsBDHudsonMBasselM, et al. Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: evidence from a sample of 659 Canadian scleroderma research group registry patients. Arthritis Care Res2009; 61(7): 966–973.
39.
MouthonLAlamiSBoisardAS, et al. Patients’ views and needs about systemic sclerosis and its management: a qualitative interview study. BMC Musculoskelet Disord2017; 18(1): 230.
40.
Occupational Therapy Practice Framework: Domain Process (3rd Edition). Am J Occup Ther2017; 68: S1–S48.
41.
BecettiKKwakkenbosLCarrierM-E, et al. Physical or occupational therapy utilization in systemic sclerosis: a scleroderma patient-centered intervention network cohort study. J Rheumatol2019; 46: 1605–1613.
